絞り込み

16421

広告

Inhibitory Effect of Afatinib on Platelet Activation and Apoptosis.

著者 Cao H , Bhuyan AAM , Umbach AT , Bissinger R , Gawaz M , Lang F
Cell Physiol Biochem.2017 Oct 27 ; 43(6):2264-2276.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (28view , 0users)

Full Text Sources

Miscellaneous

The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor afatinib is used for the treatment of several malignancies. Afatinib is at least partially effective by triggering apoptosis of tumor cells. Platelets may similarly undergo apoptosis, which is characterized by caspase 3 activation, cell shrinkage and phosphatidylserine translocation. However, an effect of afatinib on platelets has never been reported. The present study explored whether treatment of platelets with afatinib modifies platelet activation and apoptosis in the absence and presence of platelet activators thrombin or collagen related peptide (CRP).
PMID: 29073606 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード